Literature DB >> 23481418

Multifaceted effects of hydroxychloroquine in human disease.

Nancy J Olsen1, Michele A Schleich, David R Karp.   

Abstract

OBJECTIVES: Hydroxychloroquine (HCQ) is a widely used medication for the treatment of rheumatoid arthritis and systemic lupus erythematosus. An increasing body of evidence supports actions of this drug that are not directly related to its immunosuppressive or anti-rheumatic properties. The objective of this systematic review is to characterize the spectrum of conditions that might be responsive to treatment with HCQ.
METHODS: PubMed was searched using the MeSH for HCQ with relevant subheadings and the limits of human topics and English language. Four-hundred and fifty-six abstracts from this search were examined individually to exclude those that were not focused on the objectives of this review. The resulting 76 articles were grouped according to topic areas and reviewed in detail.
RESULTS: HCQ has been reported to have therapeutic effects in a wide array of conditions, including diabetes mellitus, dyslipidemias, coagulopathies, infectious diseases and malignancies. Mechanisms of action responsible for these effects likely include altered signaling through cellular receptors, post-glycosylation modifications of infectious agents, changes in levels of inflammatory mediators and inhibition of autophagy. Many of the pathways are likely dependent on drug-induced changes in intra-endosomal acidity.
CONCLUSIONS: The use of, and interest in, HCQ has spread into many areas of medicine. Actions of this drug may be directly beneficial to patients with non-rheumatic conditions such as diabetes mellitus or viral infections. Further understanding of underlying mechanisms has potential to reveal modifiable pathogenic pathways that might elucidate approaches to the design of more effective therapeutics for many chronic diseases.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimalarials; Apoptosis; Coagulopathy; Diabetes mellitus; Dyslipidemia; HIV infection; Hydroxychloroquine

Mesh:

Substances:

Year:  2013        PMID: 23481418     DOI: 10.1016/j.semarthrit.2013.01.001

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  32 in total

Review 1.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

2.  Prevention of crystalline silica-induced inflammation by the anti-malarial hydroxychloroquine.

Authors:  Rachel Burmeister; Joseph F Rhoderick; Andrij Holian
Journal:  Inhal Toxicol       Date:  2019-09-26       Impact factor: 2.724

3.  MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study.

Authors:  Mustafa Iftikhar; Ramandeep Kaur; April Nefalar; Bushra Usmani; Saleema Kherani; Isra Rashid; Etienne Schönbach; Michelle Petri; Hendrik P N Scholl; Syed M Shah
Journal:  Retina       Date:  2019-03       Impact factor: 4.256

Review 4.  Towards new avenues in the management of lupus glomerulonephritis.

Authors:  C C Mok
Journal:  Nat Rev Rheumatol       Date:  2016-01-05       Impact factor: 20.543

5.  Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines.

Authors:  Ahmed A M Abdel-Hamid; Alaa El-Din L El-Firgany
Journal:  J Mol Histol       Date:  2016-02-13       Impact factor: 2.611

6.  Symptomatic knee osteonecrosis in patients with systemic lupus erythematosus: a case-control study.

Authors:  Lidan Zhao; Xiuhua Wu; Honghua Wu; Jinmei Su; Wen Zhang; Yan Zhao; Xuan Zhang; Wenjie Zheng
Journal:  Rheumatol Int       Date:  2016-05-26       Impact factor: 2.631

Review 7.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 8.  Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Authors:  Azizul Haque; Didier Hober; Joel Blondiaux
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

9.  Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial.

Authors:  David R Karp; Benjamin F Chong; Judith A James; Cristina Arriens; Mariko Ishimori; Daniel J Wallace; Duanping Liao; Nancy J Olsen
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-11       Impact factor: 4.794

Review 10.  COVID-19, hydroxychloroquine and the importance of disease progression.

Authors:  John A Budny
Journal:  Toxicol Res (Camb)       Date:  2021-03-09       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.